175 related articles for article (PubMed ID: 38014622)
1. Safety and Clinical Effects of a Muse Cell-Based Product in Patients With Amyotrophic Lateral Sclerosis: Results of a Phase 2 Clinical Trial.
Yamashita T; Nakano Y; Sasaki R; Tadokoro K; Omote Y; Yunoki T; Kawahara Y; Matsumoto N; Taira Y; Matsuoka C; Morihara R; Abe K
Cell Transplant; 2023; 32():9636897231214370. PubMed ID: 38014622
[TBL] [Abstract][Full Text] [Related]
2. Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis - Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial).
Morimoto S; Takahashi S; Fukushima K; Saya H; Suzuki N; Aoki M; Okano H; Nakahara J
Regen Ther; 2019 Dec; 11():143-166. PubMed ID: 31384636
[TBL] [Abstract][Full Text] [Related]
3. Association of intravenous administration of human Muse cells with deficit amelioration in a rat model of spinal cord injury.
Kajitani T; Endo T; Iwabuchi N; Inoue T; Takahashi Y; Abe T; Niizuma K; Tominaga T
J Neurosurg Spine; 2021 Jan; 34(4):648-655. PubMed ID: 33385996
[TBL] [Abstract][Full Text] [Related]
4. Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients.
Imamura K; Izumi Y; Banno H; Uozumi R; Morita S; Egawa N; Ayaki T; Nagai M; Nishiyama K; Watanabe Y; Hanajima R; Oki R; Fujita K; Takahashi N; Ikeda T; Shimizu A; Morinaga A; Hirohashi T; Fujii Y; Takahashi R; Inoue H
BMJ Open; 2019 Dec; 9(12):e033131. PubMed ID: 31796494
[TBL] [Abstract][Full Text] [Related]
5. A phase II clinical trial with repeated intrathecal injections of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis.
Petrou P; Kassis I; Yaghmour NE; Ginzberg A; Karussis D
Front Biosci (Landmark Ed); 2021 Oct; 26(10):693-706. PubMed ID: 34719198
[No Abstract] [Full Text] [Related]
6. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
;
Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
[TBL] [Abstract][Full Text] [Related]
7. Intravenous Administration of Human Muse Cells Ameliorates Deficits in a Rat Model of Subacute Spinal Cord Injury.
Takahashi Y; Kajitani T; Endo T; Nakayashiki A; Inoue T; Niizuma K; Tominaga T
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834052
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial.
Imamura K; Izumi Y; Nagai M; Nishiyama K; Watanabe Y; Hanajima R; Egawa N; Ayaki T; Oki R; Fujita K; Uozumi R; Morinaga A; Hirohashi T; Fujii Y; Yamamoto T; Tatebe H; Tokuda T; Takahashi N; Morita S; Takahashi R; Inoue H
EClinicalMedicine; 2022 Nov; 53():101707. PubMed ID: 36467452
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis.
Oh KW; Moon C; Kim HY; Oh SI; Park J; Lee JH; Chang IY; Kim KS; Kim SH
Stem Cells Transl Med; 2015 Jun; 4(6):590-7. PubMed ID: 25934946
[TBL] [Abstract][Full Text] [Related]
10. Randomized placebo-controlled trial of CL2020, an allogenic muse cell-based product, in subacute ischemic stroke.
Niizuma K; Osawa SI; Endo H; Izumi SI; Ataka K; Hirakawa A; Iwano M; Tominaga T
J Cereb Blood Flow Metab; 2023 Dec; 43(12):2029-2039. PubMed ID: 37756573
[TBL] [Abstract][Full Text] [Related]
11. Phase 1b dose-escalation, safety, and pharmacokinetic study of IC14, a monoclonal antibody against CD14, for the treatment of amyotrophic lateral sclerosis.
Henderson RD; Agosti JM; McCombe PA; Thorpe K; Heggie S; Heshmat S; Appleby MW; Ziegelaar BW; Crowe DT; Redlich GL
Medicine (Baltimore); 2021 Oct; 100(42):e27421. PubMed ID: 34678870
[TBL] [Abstract][Full Text] [Related]
12. Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial.
Camu W; Mickunas M; Veyrune JL; Payan C; Garlanda C; Locati M; Juntas-Morales R; Pageot N; Malaspina A; Andreasson U; Kirby J; Suehs C; Saker S; Masseguin C; De Vos J; Zetterberg H; Shaw PJ; Al-Chalabi A; Leigh PN; Tree T; Bensimon G
EBioMedicine; 2020 Sep; 59():102844. PubMed ID: 32651161
[TBL] [Abstract][Full Text] [Related]
13. Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis.
Witzel S; Maier A; Steinbach R; Grosskreutz J; Koch JC; Sarikidi A; Petri S; Günther R; Wolf J; Hermann A; Prudlo J; Cordts I; Lingor P; Löscher WN; Kohl Z; Hagenacker T; Ruckes C; Koch B; Spittel S; Günther K; Michels S; Dorst J; Meyer T; Ludolph AC;
JAMA Neurol; 2022 Feb; 79(2):121-130. PubMed ID: 35006266
[TBL] [Abstract][Full Text] [Related]
14. Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease.
Abdul Wahid SF; Law ZK; Ismail NA; Lai NM
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011742. PubMed ID: 31853962
[TBL] [Abstract][Full Text] [Related]
15. G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: protocol for a phase II randomised, double-blind, placebo-controlled, parallel group, multicentre clinical study (STEMALS-II trial).
Salamone P; Fuda G; Casale F; Marrali G; Lunetta C; Caponnetto C; Mazzini L; La Bella V; Mandrioli J; Simone IL; Moglia C; Calvo A; Tarella C; Chio A;
BMJ Open; 2020 Mar; 10(3):e034049. PubMed ID: 32209625
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial.
Stommel EW; Cohen JA; Fadul CE; Cogbill CH; Graber DJ; Kingman L; Mackenzie T; Channon Smith JY; Harris BT
Amyotroph Lateral Scler; 2009; 10(5-6):393-404. PubMed ID: 19922130
[TBL] [Abstract][Full Text] [Related]
17. Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS: Treatment experience in clinical practice.
Meyer T; Schumann P; Weydt P; Petri S; Koc Y; Spittel S; Bernsen S; Günther R; Weishaupt JH; Dreger M; Kolzarek F; Kettemann D; Norden J; Boentert M; Vidovic M; Meisel C; Münch C; Maier A; Körtvélyessy P
Muscle Nerve; 2023 Jun; 67(6):515-521. PubMed ID: 36928619
[TBL] [Abstract][Full Text] [Related]
18. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study).
Yoshino H; Kimura A
Amyotroph Lateral Scler; 2006 Dec; 7(4):241-5. PubMed ID: 17127563
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 randomized placebo controlled double blind study to assess the efficacy and safety of tecfidera in patients with amyotrophic lateral sclerosis (TEALS Study): Study protocol clinical trial (SPIRIT Compliant).
Vucic S; Ryder J; Mekhael L; Rd H; Mathers S; Needham M; Dw S; Mc K;
Medicine (Baltimore); 2020 Feb; 99(6):e18904. PubMed ID: 32028398
[TBL] [Abstract][Full Text] [Related]
20. Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS).
Mandrioli J; Crippa V; Cereda C; Bonetto V; Zucchi E; Gessani A; Ceroni M; Chio A; D'Amico R; Monsurrò MR; Riva N; Sabatelli M; Silani V; Simone IL; Sorarù G; Provenzani A; D'Agostino VG; Carra S; Poletti A
BMJ Open; 2019 May; 9(5):e028486. PubMed ID: 31152038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]